The version of comparative effectiveness legislation is a bit better than the previous... it mentions genomics, genetics, personalized medicine.. but most of the dough goes and is going to the usual suspects and slush funds. And molecular diagnostics are still being stiffed by demands for randomized clinical trials that have nothing to do with how they would be used to fill in knowledge gaps in the real world....
Read more here
Read more here
